Lupin and Sino Universal Forge Partnership for COPD Treatment Breakthrough in China

Lupin Ltd announces a deal with China's Sino Universal Pharmaceuticals to commercialize its Tiotropium dry powder inhaler in China, targeting COPD treatment. Under the agreement, Sino Universal will handle regulatory approvals, while Lupin will manufacture the product for the Chinese market.

Pharmaceutical giant Lupin Ltd has inked a deal with Sino Universal Pharmaceuticals to bring the Tiotropium dry powder inhaler to the Chinese market, a move set to enhance treatment options for Chronic Obstructive Pulmonary Disease (COPD).

This collaboration places Lupin in charge of manufacturing, while Sino Universal will tackle regulatory approval in China, boosting patient access to top-tier respiratory treatments.

Executives from both firms expressed optimism about the synergy in advancing respiratory health, stating that the partnership is poised to expand Lupin's presence in China by delivering effective and innovative healthcare solutions.

(With inputs from agencies.)